by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug...
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC. Read More
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Bempedoic acid is an effective option for statin-intolerant patients or those needing additional low-density lipoprotein cholesterol (LDL-C) reduction, with clinical trials showing cardiovascular benefits, key drug-drug interaction...
by MM360 Staff | Jun 2, 2025 | Myeloma News
Source: Pharmacy Times articles Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer. Read More